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doi:10.1016/j.ejvs.2010.04.019Abstract Objective: To evaluate the efficacy of endovenous laser ablation of incompetent
perforating veins.
Study design: Prospective cohort study.
Patients: A total of 58 perforating veins in 33 limbs of 28 patients were treated between March
2008 and February 2009 in an outpatient clinic setting. The average age was 65 years (range
30e81 years); 64% female; CEAP clinical stage C4 (67%), C5 (17%) and C6 (16%) (Clinica,
Etiology, Anatomy and Pathophysiology, CEAP).
Methods: All patients underwent a standardised clinical examination and duplex ultrasonography.
Guided by duplex ultrasonography, the perforating veins were cannulated percutaneously and
tumescent local anaesthesia was given. An 810-nm diode laser was used to deliver 14 W power.
Mean total energy delivered was 187 (range 87e325) J. Threemonths post-treatment, all patients
underwent a further duplex ultrasound examination, to determine the treatment outcome.
Results: Occlusion of the perforating veins was achieved after 3 months in 78% of the cases. In the
CEAP C6 group, four of five ulcers had healed after 6 weeks. No serious complications, including
deep venous thrombosis, were encountered.
Conclusions: Endovenous laser therapy for treating incompetent perforating veins is a safe and
technically feasible technique. The initial occlusion rate is acceptable.
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chronic venous insufficiency (CVI) has been proposed as one
of the important therapeutic options to reduce superficial
venous hypertension.1,2 It has been shown to lead to more
rapid ulcer healing and lower recurrence rates.3e5
Endovenous laser ablation (EVLA) of truncal vein
incompetence is a widely accepted form of treatment for
CVI and has shown to be safe and effective.6e8 EVLA can be
performed in an outpatient setting under local anaesthesia
by a percutaneous approach, with the main advantages of
greater patient satisfaction (no hospital admission, no
incision required in the limb) and cost-effectiveness (less
use of hospital infrastructure). Duplex ultrasound guidance
used in endovenous techniques improves accuracy, because
the individual vessel to be treated can be visualised in
detail during the procedure.
These developments led us to believe that EVLA of
perforating veins could also benefit from the advantages
mentioned above. We were interested in whether the main
objective of this mode of treatment e stopping reflux by
occlusion of the perforator vein e could be obtained by
EVLA.
This study was designed to examine the efficacy and
safety of EVLA for the treatment of incompetent
perforating veins.
Materials and methods
Study design
Patients included in this study were those presenting to the
Centre for Phlebology Emmen, a specialised outpatient
clinic for varicose veins, for treatment of lower limb venous
disease. We included patients who attended the clinic
between March 2008 and February 2009. After an interview
using a standardised digital questionnaire and a physical
examination, all patients underwent colour duplex ultra-
sound scanning of the diseased leg. Patients were examined
in the standing position with compression applied to the
calf using a cuff-inflator or manual compression to assist in
identification of incompetent veins. All superficial saphe-
nous trunks, deep veins of thigh and calf and perforating
veins were evaluated. The severity of the chronic venous
insufficiency was graded according to the clinical
classification of the CEAP (Clinical, Etiology, Anatomy and
Pathophysiology) classification.9 All patients with a C
classification of 4 (skin changes), 5 (healed ulcer) or 6
(active ulcer) were included in the study. Within this
defined group, there were no exclusion criteria. The reason
for the cut-off point at C4 was to define the group of
patients in which we would treat the incompetent perfo-
rating veins by surgery, in accordance with the present
treatment strategy in the Netherlands.10
An incompetentperforating veinwas definedby reversal of
flow or closure of the valve longer than 300 ms. Legs with one
ormore incompetent perforating veins in the affected area of
the leg were treated by EVLA. In addition, all incompetent
saphenous trunks in the limb were also treated simulta-
neously. Informed consent was obtained from patients
undergoing treatment in the usual manner for EVLA of the
incompetent superficial venous system in the presence of CVI.Patients were treated in an outpatient clinic setting. The
procedure was performed under duplex ultrasound
guidance (Philips iU22 ultrasound system, Philips Medical
Systems, the Netherlands) with the assistance of a vascular
lab technician. A straight section of the perforating vein at
or just below the level of the fascia was identified.
Intraluminal access was achieved percutaneously using
a 21-gauge needle. The laser fibre, 400 mm diameter,
(Angiodynamics, Queensbury, NY, USA) was inserted
directly through the needle and advanced so that the
straight part of the vessel was occupied by the laser fibre
over its entire length. The needle was withdrawn slightly
to avoid contact with the laser tip. Perivascular local
tumescent anaesthesia (30 part NaCl 0.9%, 2 part
lidocaine/adrenaline (lidocaine 10 mg mle1/adrenaline
10 mg mle1), 1 part sodium bicarbonate 8.4%) was injected,
which also had the advantage of compressing the vessel
wall around the laser fibre. An 810-nm diode laser (Diomed
delta 15 W; Andover, MA, USA) was used at a power of 14 W
in the continuous mode. Laser energy was administered
over the straight section of the vessel, by pulling back the
tip slowly under ultrasound control. Careful attention was
paid to keeping the laser tip within the perforating vein
during laser activation. Our aim was to administer
between 150 and 250 J of energy, depending on the
available straight length of the perforator vein. Additional
EVLA of all incompetent truncal saphenous veins was then
performed in the same session when necessary.
Sclerotherapy or miniphlebectomy was not performed
simultaneously.
After treatment, all patients wore 35 mmHg compres-
sion stockings (Mediven Struva AG hip, Medi, Breda, the
Netherlands) for 72 h. Patients were advised to walk
regularly (at least 3 times daily for 20 min) and were
prescribed diclofenac (50 mg three times a day), a non-
steroid anti-inflammatory drug for 10 days post-procedure
as analgesia. Patients over 60 years or with symptoms
suggestive of peptic ulcer also received omeprazole (40 mg
once daily). All incompetent saphenous veins and
perforating veins were treated in one session. Bilateral
treatment was undertaken when required for management
of clinically significant venous disease.Follow-up
Six weeks after the procedure, the patients were reviewed
in the clinic and checked for any remaining ecchymosis,
pain, remaining symptoms and paraesthesia. The progress
of any leg ulcer in the treated limb was recorded. At this
review, additional sclerotherapy or miniphlebectomy of
tributary vessels was planned if necessary and performed at
a later date. After 3 months, patients underwent further
venous duplex ultrasound imaging to assess the state of all
veins treated, including perforating veins and saphenous
trunks and presence of possible thrombi in the deep venous
system.
All data were recorded prospectively in an electronic
patient database and collected in a Microsoft Excel
spreadsheet, which was also used for statistical purposes.
Table 1 CEAP (Clinical, Etiology, Anatomy and Patho-
physiology) classification and deep venous insufficiency
(n Z 33 limbs); ‘distal’ refers to deep insufficiency in the
calf only, ‘complete’ refers to thigh and calf deep vein
incompetence.
CEAP
classification
Deep venous insufficiency
none distal complete
C 4 22 (67%) 10 4 8
C 5 6 (18%) 0 3 3
C 6 5 (15%) 1 2 2
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One vascular surgeon and one physician assistant
performed all procedures during a 12-month period. In all,
58 perforating veins were treated involving 33 limbs in 28
patients. Mean patient age was 65 years (range 30e81
years) and 64% were women. The CEAP clinical class of the
33 legs treated is summarised in Table 1. Deep venous
insufficiency was present in 67% limbs (Table 1).
The average energy administered per perforating vein
treated was 187 J (range 87e325 J). Simultaneous treat-
ment of truncal incompetence was performed in 63% of
limbs: great saphenous vein (GSV) 30%; small saphenous
vein (SSV) 6%; GSV and SSV 27%. Perforator vein treatment
alone was performed in 12 of 33 limbs (36%) (Table 2).
The 3-month duplex ultrasound scans showed 45
occluded perforating veins (78%). Divided accorded to CEAP
clinical class, the occlusion rates were as follows: C4,
n Z 32 (82%); C5, n Z 10 (40%); and C6, n Z 9 (100%). Of
the simultaneously treated truncal veins, all were
occluded, of which two were partial occlusions (one GSV,
CEAP C4 group and one GSV in the C5 group).
In the C6 group of patients, four of five ulcers had healed
6 weeks after treatment; three of these limbs were treated
by perforator ablation alone (mean Z 2 perforators per
limb). No deep venous thrombosis was seen in any patient
at this assessment.
Minor complications consisted of pain in two patients of
which one had not been prescribed postoperative anal-
gesia. One patient complained of paraesthesia and, in
another case, thrombophlebitis was observed. A blister
formed in one patient from an incorrectly applied wound
dressing. No ecchymosis was observed. Recurrence of
ulcers was not recorded in this study, largely because the
follow-up period was too short to analyse this outcome.Table 2 CEAP (Clinical, Etiology, Anatomy and Pathophysiology)
(n Z 33 legs); GSV (great saphenous vein), SSV (small saphenous
CEAP C-class No. of limbs Number of limbs treated by en
Perforators alone Perforato
4 22 8 7
5 6 0 3
6 5 4 0
Total 33 12 (36%) 10 (30%)Discussion
Many methods of treating incompetent perforating veins
have been described. Until the turn of the century, surgery
was the only widely used option to prevent venous reflux.
Subfascial endoscopic perforator surgery (SEPS) tackled the
problem of the direct surgical approach and avoided
the need for an incision in the damaged skin overlying the
perforating vein to be treated. This proved to be a step
forward in the reduction of wound problems compared to
the open surgical technique.11 The necessity for general
anaesthesia for these surgical procedures resulted in
a significant proportion of patients being unsuitable for
surgical treatment.12 Limitations of SEPS due to variations
in anatomical location of perforating veins, such as in
the perimalleolar and lateral locations proved to be
a problem.13
Recent advances in endovenous interventions have
resulted in the development of different types of ultra-
sound-guided percutaneous ablation of perforating veins.14
Masuda et al. describe a 98% initial success rate by ultra-
sound-guided sclerotherapy (UGS) with a mean follow-up of
20 months and a 75% occlusion rate.15 Complications such
as hyperpigmentation and skin necrosis have been
described.16 Studies reported using radiofrequency ablation
(RFA) show high initial success rates of 90e100%, and 1-year
occlusion ranging from 46% to 79%.14
Klem et al. described the use of a cryo-probe, with the
advantage that intraluminal access to the perforating vein
is not mandatory. A 20-week success rate of 43% of treated
veins was reported.17
Proebstle et al. were the first and to date the only
authors to describe a series of 67 perforating veins treated
by EVLA.18 The legs treated were predominantly CEAP C2.
Occlusion 1 day after treatment was seen in 99% of perfo-
rating veins. At the 3-month duplex assessment, vein
diameters were measured, which remained the same, but
the occlusion rate at that time was not mentioned.
An occlusion rate of 78% at 3 months in CEAP classes
C4e6 patients in our study is comparable to results pub-
lished and presented so far.14 EVLA can be undertaken on
an outpatient basis with little post-procedure morbidity.
This allows treatment to be offered to elderly patients with
co-morbidities that would preclude anaesthesia for surgical
treatment or SEPS. In the case of liposclerotic or ulcerated
skin in the affected region where the perforator treatment
needs to take place, a percutaneous approach by EVLA
seems a safe treatment option. Another benefit is that
retreatment is easily performed should recurrence ofclassification and treatment combinations performed per leg
vein).
dovenous laser therapy
rs þ GSV Perforators þ SSV Perforators þ GSV þ SSV
1 6
1 2
0 1
2 (6%) 9 (27%)
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vein by ultrasound during the entire procedure may over-
come the problem of poor accuracy reported for surgical
treatment of incompetent perforating veins.19
One major disadvantage of this form of treatment is that
a significant ‘learning curve’ is encountered since the
ability to cannulate a small vein under ultrasound guidance
in damaged skin requires some experience and practice.
However, this is true of any new method of treatment and
only presents a temporary difficulty.
In conclusion, our study shows that EVLA of perforating
veins is a safe, effective and technically feasible tech-
nique. The above results are promising in the endeavour
towards offering complete treatment of venous reflux in
CVI by laser ablation percutaneously, under local anaes-
thesia in the outpatient clinic setting.
Our study does not attempt to identify the circum-
stances under which perforating vein surgery is useful. This
is a point which has not been systematically addressed in
any published work and would require far more detailed
study and long-term follow-up of patients with severe
venous disease.
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